for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

STADA Arzneimittel AG

STAGn.D

Latest Trade

83.60EUR

Change

0.00(0.00%)

Volume

0

Today's Range

83.60

 - 

83.60

52 Week Range

78.40

 - 

86.20

As of on the XETRA ∙ Minimum 15 minute delay

Pricing

Previous Close
83.60
Open
83.60
Volume
0
3M AVG Volume
0.82
Today's High
83.60
Today's Low
83.60
52 Week High
86.20
52 Week Low
78.40
Shares Out (MIL)
62.26
Market Cap (MIL)
5,012.33
Forward P/E
21.87
Dividend (Yield %)
0.14

Next Event

Q3 2019 STADA Arzneimittel AG Earnings Release

Latest Developments

More

STADA Arzneimittel Announces Tender Offer Results

STADA Arzneimittel: Upcoming Expiration Of Tender Offer And Intention To Delist Notes

STADA Arzneimittel: Results Of Tender Offer

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About STADA Arzneimittel AG

Stada Arzneimittel AG is a Germany-based holding company active in the pharmaceutical sector and healthcare market. The Company develops and markets products with off-patent active pharmaceutical ingredients. The Company’s primary business segments are Generics and Branded Products. The Generics segment comprises low-priced and active-ingredient products. The Branded Products segment focuses on multisource products accessible without active ingredient research, notably anti-enzymatic food intolerance drugs that are marketed by the subsidiary SCIOTEC Diagnostics Technologies. The Company's generic drugs are marketed by the Group subsidiary, STADApharm GmbH. Non-core activities of the Company encompass Commercial Business segment, which includes activities with primarily trading character such as wholesaling activities. The Company operates STADA Pharmaceuticals Australia Pty Ltd and STADA IT SOLUTIONS DOO as subsidiaries.

Industry

Biotechnology & Drugs

Contact Info

Stadastrasse 2-18

+49.6101.6030

https://www.stada.de/

Executive Leadership

Peter Goldschmidt

Chairman of the Executive Board

Guenter von Au

Independent Chairman of the Supervisory Board

Jens Steegers

Deputy Chairman of the Supervisory Board, Employee Representative

Mark Keatley

Chief Financial Officer, Member of the Executive Board

Ralph Grobecker

Managing Director of OTC segment

Key Stats

Price To Earnings (TTM)
31.21
Price To Sales (TTM)
2.17
Price To Book (MRQ)
4.54
Price To Cash Flow (TTM)
17.47
Total Debt To Equity (MRQ)
128.19
LT Debt To Equity (MRQ)
90.06
Return on Investment (TTM)
7.60
Return on Equity (TTM)
4.96

Latest News

Top PNE shareholder calls Morgan Stanley offer completely inadequate

A top shareholder in German wind energy project developer PNE <PNEGn.DE> has called a non-binding bid from an infrastructure fund run by Morgan Stanley <MS.N> "completely inadequate", a letter seen by Reuters on Wednesday said.

Germany's Stada 'very selective' on acquisitions: CEO Goldschmidt

German generic drugmaker Stada <STAGn.D> will be careful about buying businesses and companies outright, and for now will focus mainly on striking production and development deals with partners, the company's chief executive told Reuters.

UPDATE 1-Germany's Stada 'very selective' on acquisitions - CEO Goldschmidt

German generic drugmaker Stada will be careful about buying businesses and companies outright, and for now will focus mainly on striking production and development deals with partners, the company's chief executive told Reuters.

Takeda kicks off sale of Western European drugs: sources

Japan's Takeda Pharmaceutical Co <4502.T> has reached out to prospective bidders for a portfolio of drugs for sale in western Europe as it seeks to trim its debt following the $59 billion purchase of Shire, sources close to the matter told Reuters.

Factbox: Activist investor Elliott's top European holdings

U.S. activist hedge fund Elliott Management announced on Thursday it had taken a 2.1% stake in German agrichemicals and pharma company Bayer <BAYGn.DE> Here are some of New York-headquartered Elliott's top holdings in Europe (in alphabetical order):

GSK kicks off sale of $1.2 bln consumer health drugs -sources

GlaxoSmithKline (GSK) has kicked off the sale of some consumer health brands as it seeks to raise about 1 billion pounds ($1.26 billion) before pressing ahead with a spinoff of its consumer healthcare business, sources told Reuters.

Deals of the day-Mergers and acquisitions

The following bids, mergers, acquisitions and disposals were reported by 2030 GMT on Friday:

Germany's Stada buys six of GSK's consumer brands, eyes further deals

Private equity-backed generic drugmaker Stada said on Friday it would buy six consumer healthcare products from British drugmaker GlaxoSmithKline to bolster its presence in Europe.

Factbox: Activist investor Elliott's top European holdings

U.S. activist hedge fund Elliott Management announced on Wednesday that it had taken a 1.2 billion euro ($1.35 billion)stake in German technology company SAP <SAPG.DE>. [nL5N2260MG]

Activist investor Elliott's top European holdings

U.S. activist hedge fund Elliott Management announced on Wednesday that it had taken a 1.2 billion euro ($1.35 billion)stake in German technology company SAP.

UPDATE 1-Taisho said to near $1.6 bln deal for Bristol-Myers's UPSA- Bloomberg

* Taisho's sales of OTC drugs down year-on-year in April-Sept (Adds details on Taisho)

Taisho said to near $1.6 billion deal for Bristol-Myers's UPSA: Bloomberg

Japanese healthcare firm Taisho Pharmaceutical Holdings Co Ltd <4581.T> is said to be close to a $1.6 billion deal for Bristol-Myers Squibb Co's <BMY.N> French over-the-counter drugs business UPSA, Bloomberg reported on Sunday, citing sources familiar with the matter.

Factbox: Activist investor Elliott's top European holdings

U.S. activist hedge fund Elliott Management announced on Wednesday that it had taken a stake in French drinks maker Pernod Ricard <PERP.PA> worth more than 930 million euros ($1.05 billion).

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up